These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 24997153)
1. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Vallejo C; Batlle M; Vázquez L; Solano C; Sampol A; Duarte R; Hernández D; López J; Rovira M; Jiménez S; Valcárcel D; Belloch V; Jiménez M; Jarque I; Haematologica; 2014 Oct; 99(10):1632-7. PubMed ID: 24997153 [TBL] [Abstract][Full Text] [Related]
2. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Phatak P; Brissot P; Wurster M; Adams PC; Bonkovsky HL; Gross J; Malfertheiner P; McLaren GD; Niederau C; Piperno A; Powell LW; Russo MW; Stoelzel U; Stremmel W; Griffel L; Lynch N; Zhang Y; Pietrangelo A Hepatology; 2010 Nov; 52(5):1671-779. PubMed ID: 20814896 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508 [TBL] [Abstract][Full Text] [Related]
4. Deferasirox for managing iron overload in people with thalassaemia. Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446 [TBL] [Abstract][Full Text] [Related]
6. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278 [TBL] [Abstract][Full Text] [Related]
8. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Sivgin S; Eser B; Bahcebasi S; Kaynar L; Kurnaz F; Uzer E; Pala C; Deniz K; Ozturk A; Cetin M; Unal A Ann Hematol; 2012 May; 91(5):743-749. PubMed ID: 22051904 [TBL] [Abstract][Full Text] [Related]
10. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels? Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076 [TBL] [Abstract][Full Text] [Related]
11. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B; Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Vichinsky E; Bernaudin F; Forni GL; Gardner R; Hassell K; Heeney MM; Inusa B; Kutlar A; Lane P; Mathias L; Porter J; Tebbi C; Wilson F; Griffel L; Deng W; Giannone V; Coates T Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Taher A; Cappellini MD; Vichinsky E; Galanello R; Piga A; Lawniczek T; Clark J; Habr D; Porter JB Br J Haematol; 2009 Dec; 147(5):752-9. PubMed ID: 19764988 [TBL] [Abstract][Full Text] [Related]
15. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study. Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349 [TBL] [Abstract][Full Text] [Related]